Fintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...

Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...

Context Therapeutics (CNTX) has received a new Buy rating, initiated by JMP Securities analyst, Silvan Tuerkcan.Stay Ahead of the ...

Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage ...

Every investor in Silence Therapeutics plc ( NASDAQ:SLN) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 44% to be precise, ...

Context Therapeutics has a 12 month low of $0.89 and a 12 month high of $2.75. The company has a market capitalization of $76.50 million, a price-to-earnings ratio of -1.12 and a beta of 2.00.

CTIM-76 is under clinical development by Context Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop potentially first-in-class ...

Scientists have developed inhalable lung cancer therapeutics utilizing mucoadhesive proteinic nanoparticles.

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule ...

Piper Sandler has reaffirmed its Overweight rating on shares of Context Therapeutics (NASDAQ: CNTX) with a consistent price target of $4.50. The firm's confidence is bolstered by... Piper Sandler ...